F

Fanconi anemia, 1, 9 farnesyltransferase inhibitors, 97, 491 farnesyltransferase inhibitor tipifarnib, 481 fibronectin, 475 FLT3 inhibitors, 47 FLT3 mutations, 46

in AML patients, 19-20 FLT3 transmembrane tyrosine kinase, 46 fludarabine, 93, 95, 492, 662

fluorescence in situ hybridization (FISH) techniques, 17, 34, 104

18-fluoro-2-deoxyglucose positron emission tomography detection technique, 824-825 early response evaluation, 827 limitations of, 827-828 prognosis in SCT, 827 response assessment, 826-827 staging, 825-826 fms-like tyrosine kinase 3 (FLT3), 34 follicular lymphoma, 509, 515-516 agents for treating antisence oligonucleotides, 536 other drugs in, 536 stem cell transplantation, 536-537 vaccines, 536 autologous hematopoietic cell transplantation for,

677-679 classification and prognosis, 531 conventional therapy for, 716 histological transformation of, 537 monoclonal antibody therapy for, 716 prognosis and prognostic factors of, 705-707 therapy, 531-536 transplantation in, 716-718

0 0

Post a comment